![]() “Other big news we had recently was the that TROPiCS-02 trial were positive meaning that sacituzumab govitecan, an anti-TROP2 antibody-drug conjugate, after being approved in triple-negative disease is also more active than chemotherapy in the hormone receptor–positive disease. ![]() 2 The data potentially add an additional agent to the treatment landscape for this patient population. In March 2022, Gilead, the developer of sacituzumab govitecan (Trodelvy) announced that the phase 3 TROPiCS-02 trial met its primary end point of demonstrated PFS improvement among patients with hormone receptor–positive/HER2-negative advanced breast cancer vs chemotherapy. Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer (Abstract LBA1001) “DESTINY-Breast04 was the first phase 3 trial launched to confirm the paradigm of HER2-low and it was a trial which included patients with pretreated HER2-low tumors both with hormone receptor–positive and triple-negative disease…not only PFS, which was the primary end point, but also OS was improved with trastuzumab deruxtecan therapy and these might change the way we treat these patients who are pretreated with chemotherapy with or without endocrine therapy.” 1 Patients treated with the antibody-drug conjugate achieved statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS) in patients with HER2-low unresectable and/or metastatic breast cancer regardless of hormone receptor (HR) status vs physician’s choice of chemotherapy. The primary end point of the pivotal phase 3 DESTINY-Breast04 (NCT were met after fam-trastuzumab deruxtecan-nxki (Enhertu) according to a news release ahead of the 2022 ASCO meeting. Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study (Abstract LBA3) Paolo Tarantino, MD, clinical research fellow at Dana-Farber Cancer Institute in Boston, Massachusetts
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |